Eli Lilly (LLY) Rises 2% on Jefferies $1,700 Target

Eli Lilly shares rose about 2% as Jefferies set a Street-high $1,700 target and oral obesity pill Foundayo posted positive Phase 3 sleep apnea data on Monday.

Lead

Why Did Eli Lilly Stock Rise on Monday?

Lilly stock rose because two catalysts landed together: a higher Street-high target from Jefferies and a clinical readout that widens the potential use of its oral GLP-1 pill. The $1,700 target sits roughly 23% above the early-session price.

Jefferies argued that the market for obesity drugs outside the United States is underestimated. It put the addressable international patient population at roughly twice the size of the U.S. market, given the larger affluent populations abroad. The firm described obesity as an increasingly consumer-driven category, where patients choose between treatments on efficacy, tolerability, convenience and price. Jefferies also pointed to higher realized prices as patients move to higher doses, stronger margins outside the U.S., favorable economics for oral drugs and Lilly's broad obesity portfolio.

Lilly holds roughly 63% of the U.S. GLP-1 segment, helped by setbacks at rival Novo Nordisk (NVO). Because Lilly is a heavyweight in many a healthcare etf, moves in the stock also feed through to sector-wide funds.

What Did the Foundayo Sleep Apnea Trial Show?

The ATTAIN-OSA program showed that Foundayo significantly reduced obstructive sleep apnea severity, with the largest effect in patients not using positive airway pressure (PAP) therapy. The two randomized, double-blind, placebo-controlled studies ran 52 weeks and enrolled adults with moderate-to-severe sleep apnea and obesity or overweight.

• Study 1 (363 patients, no PAP): The apnea-hypopnea index, the number of breathing interruptions per hour, fell by 21.1 events per hour, a 43.8% decrease, against 4.3 for placebo. Patients lost an average of 28.0 pounds (11.5%) versus 4.4 pounds on placebo. About 31.5% reached remission or mild disease.
• Study 2 (349 patients, on PAP): The index fell by 18.3 events per hour, a 27.5% decrease, against 5.5 for placebo. Weight loss averaged 28.2 pounds (11.2%) versus 2.2 pounds on placebo. About 19.6% reached remission or mild disease.

Sleep apnea-specific hypoxic burden, a measure of oxygen deprivation during sleep, fell 55.9% in the no-PAP group and 45.8% in the PAP group. The marker of inflammation hsCRP fell by 48.9% and 38.6%, and systolic blood pressure dropped by 8.6 and 7.3 mmHg, in the two groups respectively.

Doses were escalated in 4-week steps to a maximum tolerated 9 mg, 14.5 mg or 17.2 mg. The most common side effects were gastrointestinal: nausea, diarrhea, constipation, dyspepsia and vomiting, mostly mild to moderate. Discontinuations due to adverse events reached 12.2% on Foundayo versus 3.8% on placebo in the no-PAP study, and 6.8% versus 0.6% in the PAP study.

How Does Sleep Apnea Expand Foundayo's Market?

Sleep apnea adds a second major indication to a drug that is currently approved by the FDA only for chronic weight management in adults with obesity or overweight and weight-related conditions. Lilly plans to submit Foundayo for moderate-to-severe obstructive sleep apnea in adults with obesity or overweight by the end of 2026. The indication remains investigational until a regulatory decision.

Sleep apnea is a strategic fit for Lilly. Its injectable tirzepatide is already used in the condition, so an oral option gives physicians and payers a pill-based route for patients who prefer to avoid injections. Pill formulations also carry lower manufacturing and distribution complexity than injectables, a point Jefferies cited in its margin argument.

Market Reaction and Strategic Context

Investor focus has shifted from near-term U.S. volumes to the global reach and breadth of indications of obesity drugs. Berenberg and Guggenheim have also moved positively on the stock recently, with Berenberg at $1,400. The Jefferies target now sits well above that cluster.

Canada's Drug Agency separately issued a positive reimbursement recommendation for Lilly's Alzheimer's treatment Kisunla (donanemab), adding to Monday's supportive news flow for the company.

Outlook

Lilly enters the final weeks of 2026 with a Street-high target, a second indication for Foundayo heading to the FDA and a leading U.S. GLP-1 share. The next milestones are the sleep apnea filing by year-end, the regulatory timeline that follows, and evidence of how quickly international demand develops, which Jefferies expects to be more gradual than the U.S. ramp.